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Summary
 
The leukocyte adhesion molecule, L-selectin, mediates the recruitment of lymphocytes to sec-
ondary lymphoid organs via interactions with specific ligands presented on high endothelial
venules (HEV). Although the HEV-derived ligands for L-selectin are still incompletely de-
fined, they share a common sialomucin-like structure which is thought to present clustered oli-
gosaccharides to the lectin domain of L-selectin. Podocalyxin-like protein (PCLP) is a trans-
membrane sialomucin that is similar in structure to the well-characterized L-selectin ligand
CD34. PCLP has been shown previously to be expressed on the foot processes of podocytes in
the kidney glomerulus as well as on vascular endothelium at some sites. We have determined
that PCLP is present on HEV, where it binds to both recombinant L-selectin and the HEV-
specific monoclonal antibody MECA-79. Furthermore, purified HEV-derived PCLP is able to
support the tethering and rolling of lymphocytes under physiological flow conditions in vitro.
These results suggest a novel function for PCLP as an adhesion molecule and allow the defini-
tion of conserved structural features in PCLP and CD34, which may be important for L-selec-
tin ligand function.
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M
 
aintenance of immune surveillance depends on the
constant recirculation of lymphocytes from the blood
through the vascular wall into the tissues and eventually
back into the blood (1). Lymphocyte recruitment from the
blood into all secondary lymphoid organs (except the
spleen) as well as into many sites of chronic inflammation is
mediated by specialized postcapillary venules called high
endothelial venules (HEV)
 
1
 
 (2). These vessels are defined
by the distinct, cuboidal morphology of their endothelial
cells (3) and their luminal presentation of ligands for the
leukocyte adhesion molecule, L-selectin (4). This lectin-
like adhesion molecule is responsible for the initial tether-
ing and rolling of lymphocytes on the endothelium before
their integrin-mediated firm arrest and transmigration (5,
6). Studies using antibody blockade as well as gene inacti-
vation have demonstrated the absolute requirement for
L-selectin in the recruitment of lymphocytes to peripheral
lymph nodes as well as a major role in recruitment into
Peyer’s patches and certain sites of inflammation (7–10).
The NH
 
2
 
-terminal C-type lectin domain of L-selectin
mediates adhesion by binding to specific carbohydrate
structures presented by glycoprotein ligands on the vascular
endothelium (11). The HEV-derived ligands for L-selectin
consist of a group of mucin-like glycoproteins which are
able to present dense clusters of sulfated and sialylated
O-linked oligosaccharides to L-selectin (12). Collectively,
these glycoproteins are termed the peripheral node ad-
dressin (PNAd) (13). These proteins have been identified
biochemically using either a recombinant L-selectin/IgG
chimera (14) or the mAb MECA-79, which recognizes a
sulfation-dependent posttranslational modification shared
by L-selectin ligands (13, 15, 16). Both reagents bind spe-
cifically to HEV in histologic sections, are able to block the
L-selectin–dependent adhesion of lymphocytes to HEV in
vitro
 
 
 
and in vivo
 
 
 
(15, 17, 18)
 
,
 
 and both can be used to iso-
late the same set of glycoproteins from a detergent lysate of
lymph node (16).
 
1
 
Abbreviations used in this paper:
 
 GlyCAM-1, glycosylation-dependent cell
adhesion molecule-1; HEC, high endothelial cell(s); HEV, high endothe-
lial venule(s); HPRT, hypoxanthine phosphoribosyltransferase; HUVEC,
human umbilical vein endothelial cell(s); MAdCAM-1, mucosal addressin
cell adhesion molecule-1; OSGE, 
 
O
 
-sialoglycoprotein endopeptidase;
PBS, Dulbecco’s PBS; PBST, PBS-Tween; PBS-TX, PBS–Triton X-100;
PCLP, podocalyxin-like protein; PNAd, peripheral node addressin.
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To date, four distinct ligands for L-selectin have been
identified in mouse HEV. These are CD34, glycosylation-
dependent cell adhesion molecule-1 (GlyCAM-1), mucosal
addressin cell adhesion molecule-1 (MAdCAM-1), and
Sgp200 (16, 19–21). CD34 is a transmembrane mucin-like
glycoprotein that is widely expressed on vascular endothe-
lium (22). The specific glycoform expressed by HEV car-
ries the MECA-79 epitope, binds L-selectin, and is capable
of mediating L-selectin–dependent tethering and rolling of
leukocytes under flow (16, 19, 23). GlyCAM-1 is a soluble,
secreted molecule (4) which has been shown to be able to
increase the avidity of 
 
b
 
1 
 
and 
 
b
 
2
 
 integrins on naive lym-
phocytes via ligation of L-selectin (24, 25). MAdCAM-1 is
the predominant ligand for the 
 
a
 
4
 
b
 
7
 
 integrin in the HEV of
Peyer’s patch and mesenteric lymph node (26). In addition
to its integrin-binding Ig-like domains, this molecule also
contains a mucin-like domain. A subset of MAdCAM-1 is
decorated with the MECA-79 epitope (20) and can serve as
a ligand for L-selectin (6). Sgp200 is a 200-kD sulfated gly-
coprotein which has not yet been molecularly identified
(16). In addition to these HEV ligands, P-selectin glyco-
protein ligand-1 on leukocytes (27–29) can also function as
a ligand for L-selectin.
In humans, the HEV-associated ligands for L-selectin are
still poorly defined. MECA-79 has been shown to react
with glycoproteins of 65, 105, 160, and 200-kD in human
tonsil lysates (13). CD34 represents at least part of the 105-kD
component, and it has been shown to represent 30% of the
total MECA-79–reactive protein as well as 50% of the total
adhesive activity of PNAd (23). The identities of the re-
maining glycoproteins have not yet been determined.
Based on their diverse structures and expression patterns,
the three defined ligands for L-selectin (i.e., CD34, Gly-
CAM-1, and MAdCAM-1) are likely to serve distinct roles
in lymphocyte recruitment. The identification of the re-
maining ligands should allow the dissection of their unique
functions as well as those that may be redundant.
Podocalyxin, originally identified in rat, is a sialoprotein
present at high levels on the foot processes of podocytes in
the kidney glomerulus, where it is thought to maintain the
integrity of the filtration slits by contributing to the anionic
glycocalyx of this structure (30). Although this protein re-
mains to be identified molecularly in rat, a homolog called
podocalyxin-like protein (PCLP) has been cloned from
rabbit (31) and humans (32), and a more distant chicken
homolog, known as thrombomucin, has been described re-
cently (33). Interestingly, PCLP is similar in structure to
CD34 in that both consist of a large NH
 
2
 
-terminal mucin-
like domain followed by a disulfide-containing (and pre-
sumably globular) domain, a transmembrane domain, and a
cytoplasmic tail. Additionally, CD34 (34–36) as well as
podocalyxin and its homologs (31–33, 37) are expressed on
the luminal surface of vascular endothelium in a variety of
tissues. In this study, we demonstrate that PCLP is ex-
pressed in the HEV of secondary lymphoid organs, where
it carries the MECA-79 epitope. Furthermore, MECA-
79–reactive PCLP binds to recombinant L-selectin and is
able to support the L-selectin–dependent tethering and
rolling of lymphocytes under flow. These findings support
a novel proadhesive function for PCLP in lymphocyte re-
cruitment, and suggest that common structural features of
CD34 and PCLP are important for their function as ligands
for L-selectin.
 
Materials and Methods
 
Antibodies, Carbohydrates, and Ig Chimeras.
 
Mouse anti-PCLP
mAbs 3D3 (IgG), 2A4 (IgM), and 4F10 (IgM) were generated as
described (32) and produced as hybridoma culture supernatants.
Additionally, the 3D3 antibody was produced as ascites. The
MECA-79 (rat IgM) hybridoma was obtained from the American
Type Culture Collection (Rockville, MD), produced as ascites,
and purified on Sepharose-coupled anti–rat Ig
 
k
 
 (Zymed Labora-
tories, Inc., South San Francisco, CA) as recommended by the
manufacturer. Antibodies were biotinylated with NHS-biotin
(Sigma Chemical Co., St. Louis, MO) as described (38). Purified
L-selectin mAb LAM1-3 was obtained from Dr. Thomas Tedder
(Duke University, Durham, NC). Fucoidin was purchased from
Sigma Chemical Co. L-selectin/IgG and CD4/IgG chimeras
consist of the entire extracellular domain of murine L-selectin or
human CD4 fused to the Fc domain of human IgG1. These chi-
meric proteins were collected from the supernatants of transfected
293 cells and were protein A–purified as described previously
(17). 
 
Arthrobacter ureafaciens
 
 sialidase was purchased from Oxford
GlycoSystems Plc. (Abingdon, Oxford, UK). 
 
O
 
-sialoglycoprotein
endopeptidase (OSGE) was prepared by Cedarlane Labs. Ltd.
(Hornby, Ontario, Canada) and purchased from Accurate Chem-
ical and Science Corp. (Westbury, NY).
 
Cells.
 
Jurkat T cells were obtained from the laboratory of Dr.
Art Weiss (University of California, San Francisco) and were
maintained in RPMI 1640 medium supplemented with 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin, 2 mM glutamine, and 5%
heat-inactivated FCS (Hyclone, Logan, UT). Human T lympho-
cytes were isolated from venous blood samples using standard
gradient techniques (25). In brief, blood was collected from
healthy donors, and EDTA was added to a final concentration of
5 mM to prevent clotting and cell activation. The blood samples
were diluted with 1/2 vol cation-free HBSS and layered over
Histopaque 1077 (Sigma Chemical Co.). After centrifugation at
500 
 
g
 
 for 20 min at room temperature, the mononuclear cell frac-
tion was collected, diluted in cold cation-free HBSS supple-
mented with 0.2% BSA, and centrifuged to recover the isolated
cells. T lymphocytes were obtained by depletion of B cells and
monocytes. Peripheral blood mononuclear cells were treated with
saturating amounts of mouse anti-CD14 (monocyte marker) and
mouse anti-CD19 (B cell marker) followed by sheep anti–mouse
IgG–coupled paramagnetic particles (Dynal Inc., Lake Success,
NY). Labeled cells were then removed by immunomagnetic se-
lection.
 
Immunohistochemistry.
 
Surgical specimens of human tonsil
(obtained from the University of California, San Francisco) were
either embedded in OCT medium (Miles Inc., Elkhart, IN) and
frozen, or fixed in neutral-buffered formalin and paraffin embed-
ded. Sections of paraffin-embedded human lymph node or ap-
pendix were obtained from archived specimens determined to be
devoid of specific pathology. 12-
 
m
 
m frozen sections were fixed in
1% paraformaldehyde in 100 mM cacodylate, pH 7.3, for 20 min.
For horseradish peroxidase detection, endogenous peroxidase was 
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quenched with 0.3% H
 
2
 
O
 
2
 
, 0.2 M NaN
 
3
 
 in Dulbecco’s PBS
(PBS) for 20 min. Sections were blocked with 5% goat serum and
stained with undiluted hybridoma culture supernatant overnight
at 4
 
8
 
C. The sections were then incubated sequentially with 1:250
diluted biotinylated goat anti–mouse IgG (heavy and light chain–
specific; Vector Laboratories, Inc., Burlingame, CA) in 5% goat
serum and 2.5% human serum, then with ABC elite reagent
(Vector Laboratories, Inc.) in PBS, and finally with AEC chro-
mogen (Biomeda, Foster City, CA). After chromogen develop-
ment, the sections were counterstained with aqueous hematoxy-
lin and mounted in Permafluor (Shandon Lipshaw, Pittsburgh,
PA). PBS was used for washing after each incubation. For fluores-
cence detection, frozen sections were fixed, blocked, and incu-
bated with PCLP antibodies as above. Sections were then incu-
bated sequentially with FITC-conjugated goat anti–mouse IgG
(Zymed Laboratories, Inc.) in 5% goat serum and 2.5% human
serum; 1 
 
m
 
g/ml biotinylated MECA-79 in 5% goat serum, 2.5%
human serum, and 2.5% rat serum; and Texas red–conjugated
streptavidin (Vector Laboratories, Inc.) in 5% goat serum, 2.5%
human serum, and 2.5% rat serum. The sections were washed in
PBS after each step and mounted in Vectashield (Vector Labora-
tories, Inc.).
 
PNAd Isolation.
 
Frozen surgical specimens of human tonsils
were obtained from the Cooperative Human Tissue Network,
Western Division (Case Western University, Cleveland, OH),
which is funded by the National Cancer Institute. The tissue was
homogenized in PBS containing 2% Triton X-100, 1 
 
m
 
g/ml leu-
peptin, 10 
 
m
 
g/ml aprotinin, 1 
 
m
 
M pepstatin, 10 
 
m
 
g/ml Pe-
fablock, and 5 mM EDTA in a glass/Teflon homogenizer. This
lysate was rocked at 4
 
8
 
C for 30 min followed by centrifugation at
20,000 
 
g
 
 for 20 min at 4
 
8
 
C. The lysate was then diluted twofold
with PBS and passed through a 0.2-
 
m
 
m filter. The clarified lysate
was passed over a 1-ml Sepharose 4B column (CNBr-activated;
Pharmacia Biotech, Piscataway, NJ) coupled to 2.4 mg affinity-
purified MECA-79. The column was washed with PBS contain-
ing 0.1% Triton X-100 (PBS-TX) followed by PBS containing
25 mM 
 
n
 
-octylglucoside. PNAd was then eluted with 100 mM
triethylamine containing 25 mM 
 
n
 
-octylglucoside and neutralized
with 1/10 vol 3 M Tris, pH 6.8. This material was concentrated
using a microconcentrator (Centricon-30; Amicon, Inc., Beverly,
MA), diluted with PBS containing 25 mM 
 
n
 
-octylglucoside, and
reconcentrated. The purified protein was quantified using the
BCA assay (Pierce Chemical Co., Rockford, IL), and purity was
assessed by SDS-PAGE followed by silver-enhanced alcian blue
staining (39). 7.5% gels were fixed in 25% ethanol, 10% acetic
acid overnight. They were then stained with 0.125% alcian blue
in fix solution for 1 h followed by three 30-min destaining steps
with fix solution. Gels were subsequently incubated in 5% glutar-
aldehyde in H
 
2
 
O for 1 h, followed by four 30-min washes with
10% ethanol, 5% acetic acid. This was followed by three washes
with H
 
2
 
O for 10 min each and a 30-min incubation in 0.4% sil-
ver nitrate. After rinsing briefly in water, gels were developed
with 0.013% formaldehyde in 2.5% sodium carbonate. The de-
velopment was stopped with 1% acetic acid.
 
Immunoprecipitation and Western Blotting.
 
Protein A–Sepharose
Fast Flow beads (Pharmacia Biotech) were loaded with 200 
 
m
 
l of
3D3 hybridoma culture supernatant or 6 
 
m
 
g purified mouse IgG
(Caltag Laboratories, Inc., San Francisco, CA) and washed with
PBS-TX. 100 
 
m
 
l of PBS-TX containing 
 
z
 
50 ng PNAd and 0.1 
 
m
 
l
goat serum was then added to the beads and rocked overnight at
4
 
8
 
C. The supernatant was collected and pooled with two 100-
 
m
 
l
PBS-TX washes of the beads. This unbound fraction was then
precipitated with 4 vol acetone at 
 
2
 
20
 
8
 
C for 1 h, collected by
centrifugation, dissolved in SDS-PAGE sample buffer, and
boiled. The beads were washed extensively with PBS-TX and
eluted by boiling in sample buffer. After SDS-PAGE (7.5%), the
gels were transferred in a Hoefer TE series electroblotter to
Problott (Applied Biosystems, Inc., Foster City, CA) in 10 mM
3-[cyclohexylamino]-1-propane-sulfonic acid (CAPS), 10% meth-
anol at 22 V for 16 h. The blot was then blocked in PBS contain-
ing 0.1% Tween 20 (PBST) and 3% nonfat dry milk for 1 h. Blots
were then incubated sequentially in either 1 
 
m
 
g/ml MECA-79 or
1:50 diluted 3D3 supernatant in blocking solution, 1:1,000 di-
luted biotinylated mouse anti–rat Ig
 
m
 
 (Caltag Laboratories, Inc.),
or 1:1,000 diluted biotinylated goat anti–mouse IgG (Vector Lab-
oratories, Inc.) in blocking solution, and finally 1:2,000 diluted
horseradish peroxidase–conjugated streptavidin (Caltag Laborato-
ries, Inc.) in PBST. Blots were washed with PBST after each in-
cubation and developed using an ECL substrate (Amersham
Corp., Arlington Heights, IL). For detection with the 3D3 mAb,
5–10 times more PNAd was used than for MECA-79 detection.
Quantification was performed using Sigmagel software (Sigma
Chemical Co.) after converting the data to a digital image using a
transilluminating scanner.
 
Detection of PCLP mRNA.
 
High endothelial cells (HEC) were
purified from surgical specimens of human tonsils by immuno-
magnetic selection with MECA-79 by a modification of a previ-
ously described procedure (40). After collagenase digestion of the
tonsils, stromal cells were resuspended at 2 
 
3
 
 10
 
8
 
 cells/ml in
staining buffer (PBS containing 1% BSA and 5 mM EDTA) and
incubated with 0.3 
 
m
 
g of MECA-79 per 10
 
7
 
 cells at 4
 
8
 
C for 15
min. Cells were collected by centrifugation and incubated with
30 
 
m
 
l of biotinylated mouse anti–rat Ig
 
m
 
 (Caltag Laboratories,
Inc.) for 15 min at 4
 
8
 
C. Cells were washed with staining buffer,
300 
 
m
 
l of streptavidin-coupled paramagnetic beads (Miltenyi Bio-
tec Inc., Auburn, CA) was added, and cells were incubated at 4
 
8
 
C
for 15 min. MECA-79–positive cells were isolated using an MS
 
1
 
column and a mini-MACS magnet (Miltenyi Biotec Inc.) as rec-
ommended by the manufacturer. Purity was assessed microscopi-
cally by morphologic criteria as well as MECA-79 expression by
immunofluorescence using cyanine-3–conjugated streptavidin
(Caltag Laboratories, Inc.).
Human umbilical vein endothelial cells (HUVEC) were pur-
chased from Clonetics (San Diego, CA) and were grown as rec-
ommended. Tonsillar lymphocytes were prepared by mincing
surgical specimens of human tonsil and flushing the loose lym-
phocytes through a fine screen with cold RPMI 1640 medium.
Total RNA was isolated from HEC, HUVEC, and lympho-
cytes using RNAzol B (Tel-Test, Inc., Friendswood, TX). First-
strand cDNA was made from 2 
 
m
 
g total RNA primed with random
hexamers using AMV reverse transcriptase (GIBCO BRL, Gaithers-
burg,  MD) according to the manufacturer’s recommendations.
Serial dilutions of cDNA were amplified using Klentaq polymerase
mix (Clontech, Palo Alto, CA) and the following primers: for
PCLP, 5
 
9
 
-TTTGGATCCCAGATGCCAGCCAGCTCTACG-3
 
9
 
and 5
 
9
 
-TTTGAATTCCTTCATGTCACTGACCCCTGC-3
 
9
 
were used, and for hypoxanthine phosphoribosyltransferase (HPRT),
5
 
9
 
-CCTGCTGGATTACATCAAAGCACTG-3
 
9
 
 and 5
 
9
 
-TCC-
AACACTTCGTGGGGTCCT-3
 
9
 
 were used. One half of the re-
sulting amplified DNA was electrophoresed on 1% agarose gels
and visualized by ethidium bromide staining. Quantification was
performed using ImageQuant software (Molecular Dynamics,
Sunnyvale, CA) on digital images of gels obtained by optical
scanning of photographs.
 
Purification of MECA-79–reactive PCLP.
 
A detergent lysate was
prepared from 10 g of human tonsils as described for PNAd isola- 
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tion. This material was passed twice over a 2-ml column of protein
A–coupled Sepharose. The unbound material was then passed
over a 0.5-ml protein A column to which 2 ml of 3D3 ascites had
been bound and covalently coupled with dimethyl pimelimidate
(Pierce Chemical Co.) as described (38). After washing with
PBS-TX, the bound material was eluted with 100 mM triethyl-
amine containing 0.1% Triton X-100 and neutralized with 1/10
vol 3 M Tris, pH 6.8. This sample was then purified on MECA-
79–coupled Sepharose as described for PNAd isolation. 1/60 of
the resulting material was analyzed by SDS-PAGE followed by
MECA-79 Western blotting.
 
Parallel Plate Flow Chamber Analysis.
 
Purified PCLP was di-
luted 1:10 or 1:20 in Tris-buffered saline, pH 8.5, and coated
onto bacteriological Petri dishes (Corning, Corning, NY) at 4
 
8
 
C
overnight. For blocking, the plates were treated with 3% BSA for
1 h at room temperature. The substrate-coated slides were incor-
porated as the lower wall in a parallel plate flow chamber and
mounted on the stage of an inverted phase–contrast microscope
(Diaphot 200; Nikon, Inc., Melville, NY). All flow experiments
were performed at room temperature. The wall shear stress was
calculated as described previously (41). Cells were stored at a con-
centration of 10
 
7
 
 cells/ml in cation-free HBSS containing 0.2%
BSA, and were diluted 1:10 in HBSS containing 0.2% BSA im-
mediately before perfusion into the flow chamber. Jurkat cells
were infused into the chamber at a shear stress of 0.8 dynes/cm
 
2
 
and T lymphocytes at 1.25 dynes/cm
 
2
 
. After three min, the cell
tethering rate (number of cells that tethered per minute per field)
was determined by analysis of two to four fields of view. Tether-
ing was defined as the initial adhesive event, which results in the
capture of a flowing cell by the substrate-coated surface. Cell
tethering was followed by either continuous rolling or detach-
ment from the substrate. Both types of interactions were included
in the calculation of tethering rate. For inhibition studies, the cells
(10
 
7
 
/ml) were preincubated for 20 min in cation-free HBSS con-
taining 0.2% BSA with 150 
 
m
 
g/ml LAM1-3 (anti–L-selectin) or
100 
 
m
 
g/ml fucoidin (Sigma Chemical Co.). The cell suspension
was diluted 10-fold with HBSS containing 0.2% BSA before in-
fusion into the flow chamber. The substrate was incubated with
MECA-79 (ascites diluted 1:20) or 3D3 (anti-PCLP, ascites di-
luted 1:20) for 1 h at room temperature. Immobilized PCLP was
treated with 50 mU/ml of sialidase in 0.1 M sodium acetate, pH
5.0, for 1 h at room temperature, or with 0.1 M sodium acetate,
pH 5.0, alone as a control. OSGE was diluted 10-fold in PBS to a
concentration of 0.24 mg/ml total protein, and was used to treat
immobilized PCLP for 1 h at room temperature.
 
Results
 
HEC Express PCLP.
 
Since PCLP and its homologs are
expressed by vascular endothelium in a number of sites (see
above), we sought to determine if PCLP was present in
HEV. Three different mAbs specific for human PCLP were
used for immunohistochemical staining of sections of hu-
man secondary lymphoid organs. Two-color immunofluo-
rescence experiments were performed by simultaneously
staining frozen sections of human tonsil with a PCLP mAb
(4F10) and MECA-79. As shown in Fig. 1, HEV were ob-
served that expressed both PCLP and the MECA-79
epitope. PCLP was concentrated at the surface of the HEC
on the luminal aspect of the vessels. Similar staining pat-
terns were obtained with two other PCLP mAbs (3D3 and
2A4, not shown). Localization to the luminal face of vascu-
lar endothelium has also been reported for podocalyxin in
kidney (30) and for thrombomucin in multiple tissues (33).
HEV of paraffin-embedded samples of lymph node and ap-
pendix were also stained by the PCLP mAb 2A4 using im-
munoperoxidase techniques (Fig. 2, 
 
A
 
–
 
C
 
), demonstrating
that PCLP expression was present in HEV of both mucosal
and nonmucosal lymphoid organs.
PCLP expression was not restricted to HEV, as staining
was associated with endothelial cells of many classes of
blood vessels in these lymphoid organs. Fig. 2 shows PCLP
staining in muscular arteries (Fig. 2 
 
D
 
), arterioles (Fig. 2 
 
E
 
),
and capillaries (
 
arrowheads
 
, Fig. 2 
 
B
 
). These findings extend
those of previous studies which demonstrated the expres-
sion of podocalyxin and its homologs on vascular endothe-
lium in nonlymphoid tissues (30, 32, 33).
It was also apparent from these experiments that al-
though the majority of HEV in tonsils were positive for
PCLP expression, a minority were weak or negative (Fig. 2 
 
A
 
).
Figure 1. Coexpression of MECA-79 and PCLP in HEV of tonsil. Frozen sections were stained simultaneously with the PCLP mAb 4F10 (A) and
MECA-79 (B). A and B show the same HEV viewed with an FITC filter (A) or a Texas red filter (B). 
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This observation was also noted in the two-color immu-
nofluorescence experiments, where some MECA-79–posi-
tive vessels expressed little or no PCLP. In contrast, CD34
can be detected on virtually all HEV in sections of the same
tonsil (not shown). However, these PCLP-negative HEV
were not noted in lymph node or appendix, suggesting that
the heterogeneity might have been the result of the in-
flamed state of the tonsil specimens.
A reverse transcriptase PCR assay was used to demon-
strate the presence of PCLP mRNA in purified HEC.
MECA-79–expressing cells were purified from collage-
nase-digested tonsillar stroma by immunomagnetic selec-
tion. This procedure produced 99% pure HEC with a slight
contamination of lymphocytes, as determined by morphol-
ogy and MECA-79 expression. Total RNA was extracted
from HEC, tonsillar lymphocytes, and primary cultured
endothelial cells (HUVEC). Serial dilutions of reverse-tran-
scribed cDNA were then amplified with primers specific
for PCLP or HPRT. The level of the constitutively ex-
pressed HPRT mRNA was used to normalize the amount
of total cDNA in each sample. PCLP mRNA was readily
detected in both HEC and HUVEC cDNA, but was only
barely detectable in the lymphocyte sample (Fig. 3). The
identity of the product that was amplified using PCLP-spe-
Figure 2. Expression of PCLP in secondary lymphoid organs. Frozen sections of tonsil and associated connective tissue (A and D) and paraffin-embed-
ded sections of tonsil (E and F), appendix (B), and lymph node (C) were stained with the anti-PCLP mAb 2A4. Arrows, HEV. Arrowheads, PCLP-express-
ing capillaries. Bars, 200 mm (A), 100 mm (B, D, E, and F), and 50 mm (C). Data are representative of two different samples of tonsil and lymph node,
and three samples of appendix.1970 Podocalyxin-like Protein Is an L-selectin Ligand
cific primers was confirmed by the demonstration of appro-
priately sized fragments after digestion with the restriction
endonucleases Sac1 and Sty1 (data not shown). When the
data were quantified and normalized for HPRT expression,
PCLP mRNA levels were found to be approximately two-
fold greater in HUVEC than in HEC. Importantly, the
PCLP expression level in HEC was at least 32-fold higher
than in the lymphocyte sample, thus showing that the
PCLP mRNA detected in the HEC preparation was not a
result of lymphocyte contamination. Additionally, when
reverse transcriptase was omitted from the cDNA reactions,
no PCR product was observed (Fig. 3, (2)RT lanes), es-
tablishing that all products are the result of amplified
cDNA and not contaminating genomic DNA.
Tonsillar PCLP Displays the MECA-79 Epitope and Binds
L-selectin. To determine whether HEV-derived PCLP
carries the MECA-79 epitope and is therefore a potential
ligand for L-selectin, we subjected MECA-79–purified
tonsil lysate (i.e., PNAd) to Western blotting with the
PCLP mAb 3D3 as well as MECA-79 (Fig. 4 A). MECA-79
detected major bands of 210, 160, 115, and 60 kD, in
agreement with previous characterizations (13). The 3D3
antibody specifically recognized a 160-kD component in
PNAd, which is consistent with the molecular weight of
PCLP.
The identity of the 160-kD component of PNAd as
PCLP was confirmed by immunoprecipitation with the
3D3 antibody (Fig. 4 B). When PNAd was immunoprecip-
itated with 3D3, the 160-kD band was specifically depleted
from the unbound fraction, and only this component was
detected in the bound fraction. This result demonstrates
that the 160-kD band represented a MECA-79–reactive
form of PCLP. In multiple experiments, the 3D3 antibody
reproducibly depleted a maximum of 50% of the 160-kD
band. Increasing the amount of antibody did not enhance
the precipitation, suggesting that there were glycoforms of
HEV-derived PCLP that were unreactive with the 3D3
antibody. Since this antibody was made against a nonglyco-
sylated form of recombinant PCLP produced in bacteria,
the existence of an unreactive native glycoform would not
be surprising. However, it is formally possible that the un-
reactive material represented a distinct glycoprotein with
the same apparent molecular weight.
To demonstrate a direct interaction between HEV-derived
PCLP and L-selectin, the same preparation of PNAd was
subjected to precipitation with a recombinant L-selectin/
IgG chimera (Fig. 5). Essentially all of the PCLP band
(160 kD) and .90% of the total PNAd were precipitated
with the L-selectin/IgG chimera, whereas no interaction
was observed between any PNAd component and a con-
trol CD4/IgG chimera. Furthermore, the L-selectin–
bound material could be eluted by the addition of EDTA.
This demonstrates that PCLP and CD34, as well as the two
unidentified PNAd components (210 and 65 kD), inter-
acted with L-selectin in a calcium-dependent manner, a
characteristic of selectin–carbohydrate interactions (12).
HEV-derived PCLP Is a Sialomucin. All HEV-derived
L-selectin ligands described to date share a common sialo-
mucin-like character (12, 23). Similarly, PCLP derived
from the kidney glomerulus or microvascular endothelium
is known to be modified extensively with sialylated oli-
gosaccharides, a hallmark of sialomucins (31, 42). We
sought to determine if the specific form of PCLP that is
produced by HEV exhibits these structural features. There-
Figure 3. Detection of PCLP mRNA
by PCR. Fragments of the PCLP and
HPRT sequences were amplified by
PCR from serial dilutions of cDNA
from purified HEC, tonsillar lympho-
cytes, and HUVEC. (-)RT, PCR reac-
tions using samples from which the re-
verse transcriptase was omitted. Note
that a faint PCLP band is barely visible
in the lowest dilution of lymphocyte
cDNA.
Figure 4. Western blotting and immunoprecipitation of PNAd with
PCLP mAb. (A) PNAd was electrophoresed on 7.5% SDS gels and blot-
ted with either MECA-79, the PCLP mAb 3D3, or control mouse IgG.
(B) Samples of PNAd were immunoprecipitated (I.P.) with protein
A–Sepharose loaded with either 3D3 (PCLP mAb) or control mouse
IgG. The unbound supernatant (SUP) as well as the fraction bound to the
antibody (PEL) were analyzed by MECA-79 Western blotting after 7.5%
SDS-PAGE.
Figure 5. Binding of PNAd
to L-selectin. Samples of PNAd
were precipitated with protein A
beads loaded with either L-selec-
tin–IgG (L-IgG) or with CD4/
IgG chimeras (CD4-IgG). The
unbound supernatants (SUP) and
EDTA elutions of bound mate-
rial (EDTA) were electrophoresed
on a 7.5% SDS gel and Western
blotted with MECA-79. Arrow-
head, The 160-kD band repre-
senting PCLP.1971 Sassetti et al.
fore, we subjected PNAd to digestion with OSGE, an en-
dopeptidase that specifically hydrolyzes the peptide back-
bone of sialomucins (43). When PNAd was treated with
OSGE, virtually all of the material detected by MECA-79
was eliminated, including the 160-kD PCLP band (Fig. 6).
Interestingly, no low molecular weight cleavage products
were detected, suggesting that either the resulting cleaved
products were very small or that an intact peptide back-
bone is essential for the presentation of the MECA-79
epitope.
To demonstrate directly the sialylation of HEV-derived
PCLP, we subjected PNAd to sialidase digestion followed
by Western blotting with the 3D3 antibody. This treat-
ment resulted in a clear increase in the electrophoretic mo-
bility of PCLP, thus confirming the presence of sialic acid
(Fig. 6). In contrast, removal of sialic acid from many gly-
coproteins (35, 44), including glomerular PCLP (30, 45),
results in a decrease in mobility due to a loss of charge.
However, the behavior of HEV-derived PCLP was similar
to that of the other PNAd components (data not shown),
including GlyCAM-1 and CD34 (14). The sensitivity of
the HEV-derived form of PCLP to both OSGE and siali-
dase demonstrates that it is sialomucin-like in structure, as
is the case for all MECA-79–reactive ligands in HEV (3).
Western blotting of PNAd with the 3D3 antibody often
revealed a high molecular weight band (.200 kD) in addi-
tion to the major 160-kD band (Fig. 6). We suspect that
this high molecular weight species represented an SDS-sta-
ble multimerized form of PCLP, which has been described
previously (45). The molecular weight of this band did not
correspond to the major 210-kD component of PNAd.
However, a minor band with a similar molecular weight to
this putative multimer was observed occasionally in PNAd,
and likely represented the same species (Fig. 6).
PCLP Mediates L-selectin–dependent Adhesion under Flow.
PNAd, as well as CD34 isolated from PNAd, have been
shown to support the L-selectin–dependent tethering and
rolling of lymphocytes under flow conditions (23). There-
fore, we wished to examine whether HEV-derived PCLP
isolated from human tonsils shared these properties.
MECA-79–reactive PCLP was purified from detergent ly-
sates of tonsil by sequential purification on 3D3-coupled
Sepharose and MECA-79–coupled Sepharose. Western
blotting of the purified material with MECA-79 showed a
major band of 160 kD, as expected (Fig. 7 A). This material
was coated onto one surface of a parallel plate laminar flow
chamber, and either peripheral blood T lymphocytes or Jurkat
T lymphoma cells were infused into the chamber at physi-
ological flow rates. Under these conditions, both cell types
tethered to the PCLP-coated surface (Fig. 7 B), but not to
a surface coated with BSA. The rolling behavior of Jurkat
Figure 6. OSGE and sialidase
digestion of PCLP. PNAd was
either treated with OSGE and
Western blotted with MECA-
79, or treated with sialidase and
blotted with the PCLP mAb
3D3. Mock treatments were
identical except the enzyme was
omitted. Arrowhead, The 160-kD
PCLP band. Small arrow, The
presumed PCLP multimer.
Figure 7. Tethering of lymphocytes to purified PCLP under flow. (A) MECA-79 Western blotting of the purified PCLP, which was used in the flow
chamber experiments, showing a major band at 160 kD. (B) Peripheral blood T lymphocytes or Jurkat T lymphoma cells were infused into the flow
chamber at a constant wall shear stress, and the cell tethering rate to the PCLP-coated surface was determined. (C) Immobilized PCLP was treated with
OSGE, sialidase, MECA-79, or PCLP mAb (3D3) before infusion of Jurkat cells. Jurkat cells were treated with L-selectin mAb (LAM1-3) or fucoidin be-
fore infusion. Error bars represent SD of measurements from at least three separate fields of view.1972 Podocalyxin-like Protein Is an L-selectin Ligand
cells was studied in detail. At 0.8 dynes/cm2, the velocity of
Jurkat cells rolling on PCLP was 50.1 6 14.1 mm/s, which
was comparable to the velocity of these cells rolling on un-
fractionated PNAd (data not shown). This adhesion was
dependent on L-selectin (Fig. 7 C), since it was inhibited
completely by pretreatment of the Jurkat cells with either
an L-selectin mAb or the L-selectin antagonist fucoidin
(46). Furthermore, treatment of the coated PCLP with ei-
ther OSGE or A. ureafaciens sialidase abrogated the interac-
tion with Jurkat cells, consistent with the sialomucin-like
structure of PCLP and the absolute requirement of sialic
acid for L-selectin binding. Finally, treatment of the coated
substrate with MECA-79 abrogated all interactions with
Jurkat cells, establishing that lymphocyte L-selectin was
binding to the immobilized PCLP and not to a MECA-
79–unreactive contaminant. In contrast, treatment of the
immobilized PCLP with the 3D3 antibody did not affect
lymphocyte adhesion. This result was not surprising, since
this antibody recognizes a protein determinant (32). Based
on these data, we conclude that immobilized MECA-79–
reactive PCLP was able to mediate the L-selectin–depen-
dent tethering and rolling of lymphocytes under physiolog-
ical flow conditions.
Discussion
Previously, it was speculated that PCLP on endothelial
cells might serve as an antiadhesion molecule due to its
strong negative charge, which in the kidney glomerulus ap-
pears to be involved in maintaining the filtration slits be-
tween podocyte foot processes via charge repulsion (31).
This study demonstrates that PCLP is present on the lumi-
nal face of HEV, where it can serve as a proadhesive ligand
for the leukocyte adhesion molecule, L-selectin. This HEV-
derived PCLP was shown to bind to both recombinant
L-selectin and the HEV-specific mAb MECA-79. Further-
more, MECA-79–reactive PCLP was capable of supporting
the L-selectin–dependent tethering and rolling of lympho-
cytes under flow, demonstrating that PCLP has the ability
to function as a ligand for L-selectin and therefore poten-
tially participate in the recruitment of blood-borne lym-
phocytes to secondary lymphoid organs.
The ability of PCLP to function as both an antiadhesive
molecule on the podocyte and a proadhesive molecule in
HEV is likely imparted by tissue-specific posttranslational
modifications. Evidence for this differential modification is
provided by the distinct electrophoretic behavior of glomer-
ulus- and HEV-derived PCLP after sialidase treatment, and
the observation that HEV-derived PCLP binds to the
MECA-79 antibody, which does not stain glomerular tis-
sue (47). Both sulfation and fucosylation of HEV ligands
are required for L-selectin binding (16, 48). Furthermore,
HEV-derived GlyCAM-1 has been demonstrated to dis-
play both galactose-6-SO4 and N-acetyl-glucosamine-6-SO4
in the context of 69- and 6-sulfo-sialyl Lewisx, respectively
(49–51). Therefore, we suspect that the elaboration of these
or related capping structures by HEC is essential for the
function of PCLP as an adhesive ligand for L-selectin.
The expression of PCLP on both platelets and early he-
matopoietic progenitors (33) raises the possibility that this
molecule may function as a selectin ligand at these sites as
well as in HEV. Strong evidence has been presented for the
existence of a ligand for P-selectin on platelets (52–54) and
a ligand for L-selectin on the early hematopoietic progeni-
tor cell line KG1a (55). Therefore, it is tempting to specu-
late that PCLP could be involved in a multitude of selec-
tin-mediated adhesive interactions between endothelium,
hematopoietic cells, and platelets.
Interestingly, PCLP shows striking similarities to CD34
in both general structure and expression pattern. In addi-
tion to a membrane-distal mucin-like domain, both pro-
teins contain a membrane-proximal cysteine-rich domain,
a transmembrane domain, and a sizable cytoplasmic tail.
The mucin domains of PCLP and CD34 are characterized
by a high content of serine, threonine, and proline, and in
contrast to many other mucin-like proteins (56, 57), do not
exhibit any obvious sequence repeats. As with CD34,
dense  O-glycosylation of the mucin domain is inferred be-
cause of the limited number of potential sites for N-glyco-
sylation and the threefold discrepancy between the pre-
dicted molecular weight of the peptide and the apparent
molecular weight of the glycoprotein by SDS-PAGE. The
sensitivity of PCLP and CD34 (23) to OSGE and sialidase
confirms that these proteins are sialomucin-like in struc-
ture. PCLP and CD34 differ in the length of their mucin
domains, z290 and 130 amino acids long, respectively, and
share no obvious sequence homology here. Despite these
differences, the mucin domains of PCLP and CD34 are
presumably responsible for direct interaction with L-selec-
tin, since all of the HEV-derived L-selectin ligands that
have been biochemically defined to date contain mucin-
like domains (3, 23).
COOH-terminal to their mucin-like domains, PCLP
and CD34 contain regions with four and six cysteines, re-
spectively, which likely form globular structures (see pp.
215–216 of reference 58). Following these domains and the
predicted transmembrane regions are cytoplasmic tails,
which are likely to serve essential functions, since the se-
quence of each has been highly conserved across species.
Thus, the cytoplasmic tail of human CD34 shares .90%
amino acid identity with its mouse and canine homologs
(34, 59, 60), and this region of human PCLP shares 96%
identity with its rabbit homolog and 84% identity with
thrombomucin, its chicken homolog (31–33). Strikingly, it
is also this region that is the most homologous between
PCLP and CD34. These domains are nearly the same
length, containing 75 and 74 amino acids in human PCLP
and CD34, respectively, and share 25% identity overall.
Moreover, there are three short segments which share
.50% identity (Fig. 8). These observations not only sup-
port a possible evolutionary relationship of these two pro-
teins, but also suggest the importance of the conserved re-
gions in some common function. One possibility is a
similar role in cell signaling. This possibility is supported by
the presence of multiple potential serine/threonine kinase
sites in both molecules (Fig. 8; references 32 and 61) and1973 Sassetti et al.
the observation that CD34 is phosphorylated after protein
kinase C activation (62). This domain could also function in
directing the specific cellular localization of these molecules.
Given the similar structures and expression patterns of
PCLP and CD34, it has been suggested that they could
serve redundant roles under some circumstances. In partic-
ular, it was proposed that the lack of a drastic hematopoietic
defect in the CD34 knockout mouse could be due to com-
pensation by PCLP (33). Similarly, it is possible that the
lack of a defect in lymphocyte recruitment to secondary
lymphoid organs in these mice (63) might be due to com-
pensation by PCLP or possibly other PNAd components.
Although this interpretation implies some functional re-
dundancy between these molecules, their coexpression in
HEV suggests that they may possess distinct functions as
well. Thus far, it has been demonstrated that both CD34
and PCLP are able to mediate the L-selectin–dependent
tethering and rolling of lymphocytes under flow, but a di-
rect comparison may be required to uncover distinct roles
for these two glycoproteins in this process.
This study contributes to the definition of the endothe-
lial ligands for L-selectin. In human tonsil, there are cur-
rently two MECA-79– and L-selectin–reactive glycopro-
teins, of 210 and 65 kD, which do not react with
antibodies to either CD34 or PCLP. It remains to be deter-
mined whether the 65-kD component represents the hu-
man homolog of GlyCAM-1 or MAdCAM-1 (64). The
210-kD component is likely to represent the homolog of
mouse Sgp200. The identification of CD34 and PCLP as
HEV ligands for L-selectin, in conjunction with the identi-
fication of these additional ligands, will allow the dissection
of both the distinct and redundant roles of each in the re-
cruitment of lymphocytes from the blood via HEV.
Figure 8. Alignment of PCLP and CD34 cytoplasmic tails. Regions
depicted encompass residues 281–354 of human CD34, 309–382 of
mouse CD34, 453–528 of human PCLP, and 477–551 of rabbit PCLP,
and begin immediately after the predicted transmembrane domain of each
protein. Regions of .50% homology are boxed. Potential protein kinase
C (S/T-X-R/K) and casein kinase II (S/T-XX-D/E) phosphorylation
sites are circled.
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